Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2017 (2017), Article ID 1367159, 7 pages
https://doi.org/10.1155/2017/1367159
Research Article

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

1University of Florida Health Cancer Center-Orlando Health, Orlando, FL, USA
2University of Central Florida College of Medicine, Orlando, FL, USA
3Department of Radiation Oncology, University of Florida, Gainesville, FL, USA

Correspondence should be addressed to Patrick Kelly

Received 2 May 2017; Accepted 20 August 2017; Published 25 September 2017

Academic Editor: Debra A. Tonetti

Copyright © 2017 Patrick Kelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar
  2. J. R. Harris, Diseases of the Breast, Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2010.
  3. C. D. Hart, I. Migliaccio, L. Malorni, C. Guarducci, L. Biganzoli, and A. Di Leo, “Challenges in the management of advanced, ER-positive, HER2-negative breast cancer,” Nature Reviews Clinical Oncology, vol. 12, no. 9, pp. 541–552, 2015. View at Publisher · View at Google Scholar
  4. S. Hellman and R. R. J. Weichselbaum, “Oligometastases,” Journal of Clinical Oncology, vol. 13, no. 1, pp. 8–10, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. S. S. Lo, S. D. Moffatt-Bruce, L. A. Dawson et al., “The role of local therapy in the management of lung and liver oligometastases,” Nature Reviews Clinical Oncology, vol. 8, no. 7, pp. 405–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Huang, G. Wu, and K. Yang, “Oligometastasis and oligo-recurrence: More than a mirage,” Radiation Oncology, p. 230, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. P. R. Patel, D. S. Yoo, Y. Niibe, J. J. Urbanic, and J. K. Salama, “A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer,” Pulmonary Medicine, Article ID 480961, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Butte, M. Gönen, P. J. Allen et al., “Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection,” Annals of Surgical Oncology, vol. 22, no. 8, pp. 2761–2771, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Iyengar, B. D. Kavanagh, Z. Wardak et al., “Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 32, no. 34, pp. 3824–3830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Weickhardt, B. Scheier, J. M. Burke et al., “Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer,” Journal of Thoracic Oncology, vol. 7, no. 12, pp. 1807–1814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Straka, D. W. N. Kim, R. D. Timmerman, I. Pedrosa, C. Jacobs, and J. Brugarolas, “Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months,” Journal of Clinical Oncology, vol. 31, no. 23, pp. e401–e403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Mayo, M. C. De Jong, C. Pulitano et al., “Surgical management of hepatic neuroendocrine tumor metastasis: Results from an international multi-institutional analysis,” Annals of Surgical Oncology, vol. 17, no. 12, pp. 3129–3136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. E. Rusthoven, S. F. Hammerman, B. D. Kavanagh, M. J. Birtwhistle, M. Stares, and D. R. Camidge, “Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis,” Acta Oncologica, vol. 48, no. 4, pp. 578–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. National Comprehensive Cancer Network, Non-Small Cell Lung Cancer, Version 8, 2017.
  15. N. C. Turner, J. Ro, F. André et al., “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer,” New England Journal of Medicine, vol. 373, no. 3, pp. 209–219, 2015. View at Publisher · View at Google Scholar
  16. R. S. Mehta, W. E. Barlow, K. S. Albain et al., “Combination anastrozole and fulvestrant in metastatic breast cancer,” New England Journal of Medicine, vol. 367, no. 5, pp. 435–444, 2012. View at Publisher · View at Google Scholar · View at Scopus